Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Crossing the HLA barriers.

Yair Reisner1, Hilit Gur, Shlomit Reich-Zeliger

  • 1Department of Immunology, The Weizmann Institute of Science, 76100 Rehovot, Israel. yair.reisner@weizmann.ac.il

Blood Cells, Molecules & Diseases
|November 6, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sequential Roles of VLA-4/VCAM-1 Interactions and CXCR4/CXCL12 Cues in the Early Phases of Injured Lung Regeneration by Lung Cell Transplantation.

American journal of respiratory cell and molecular biology·2025
Same author

Anti-viral CD8 central memory veto cells as a new platform for CAR T cell therapy.

Stem cells translational medicine·2025
Same author

Independent and temporally separated dynamics for RORγt and Foxp3 during Th17 differentiation.

Frontiers in immunology·2025
Same author

Overcoming NK-mediated rejection by anti-3<sup>rd</sup>-party central memory veto CD8 T cells through downregulation of DNAM-1 on alloreactive NK cells.

Cell reports·2025
Same author

RORc-expressing immune cells negatively regulate tertiary lymphoid structure formation and support their pro-tumorigenic functions.

Journal of hepatology·2024
Same author

From Epithelium to Therapy: Transitional Cells in Lung Fibrosis.

American journal of respiratory cell and molecular biology·2024
Same journal

Compound heterozygous variants in F7 gene causing severe factor VII deficiency without bleeding: A genotypic and laboratory analysis.

Blood cells, molecules & diseases·2026
Same journal

Propofol attenuates H<sub>2</sub>O<sub>2</sub>-induced senescence in human umbilical vein endothelial cells by activating the NRF2/HO-1 axis.

Blood cells, molecules & diseases·2026
Same journal

Is it time to implement a hemorheology passport in sickle cell disease?

Blood cells, molecules & diseases·2026
Same journal

From blood viscosity to a hemorheology passport: Making sickle-cell monitoring clinically actionable.

Blood cells, molecules & diseases·2026
Same journal

A real-world analysis of polycythemia vera at two comprehensive cancer centers in Cali, Colombia.

Blood cells, molecules & diseases·2026
Same journal

Sickle Cell Disease: Can genetic variability influence pregnancy outcomes?

Blood cells, molecules & diseases·2026
See all related articles

Megadose hematopoietic progenitor transplants overcome genetic barriers. Veto cells, like CD34+ cells and specific cytotoxic T lymphocytes (CTLs), induce tolerance by promoting apoptosis in host T cells, enabling safer transplantation strategies.

Area of Science:

  • Immunology
  • Transplantation Biology
  • Cellular Therapy

Background:

  • Hematopoietic progenitor transplantation (HPCT) can overcome major genetic barriers when using high cell numbers ('megadose' transplants).
  • Veto cells within hematopoietic progenitor populations are hypothesized to facilitate tolerance in HPCT.
  • Understanding veto cell mechanisms is crucial for improving transplant outcomes and reducing graft-versus-host disease (GVHD).

Purpose of the Study:

  • To investigate the role and mechanisms of veto cells in inducing tolerance during HPCT.
  • To explore the potential of different veto cell populations, including CD34+ cells and cytotoxic T lymphocytes (CTLs), for tolerance induction.
  • To develop strategies for separating veto activity from graft-versus-host disease (GVHD).

Main Methods:

Related Experiment Videos

  • In vitro mixed-lymphocyte reactions (MLRs) using purified CD34+ cells and bulk MLRs.
  • Assessment of veto cell activity using caspase inhibitors (e.g., BD-FMK) to detect apoptosis.
  • Ex vivo expansion of early myeloid CD33+ cells and generation of anti-third party CTLs under IL2 deprivation.
  • In vivo studies to evaluate the safety and efficacy of veto CTLs for tolerance induction.

Main Results:

  • Purified CD34+ cells suppressed donor-specific CTLs in MLRs, indicating veto activity.
  • Veto activity of CD34+ cells involves cell contact and induces apoptosis in effector host T cells.
  • Expanded CD33+ myeloid cells and specifically generated anti-third party CTLs also demonstrated veto activity.
  • Anti-third party CTLs generated under IL2 deprivation induced tolerance without causing GVHD in vivo.

Conclusions:

  • Veto cells, including CD34+ progenitors and specific CTL subsets, play a critical role in facilitating tolerance during HPCT.
  • The mechanism of veto activity involves T cell deletion via apoptosis.
  • Generating anti-third party CTLs under selective conditions (IL2 deprivation) allows for safe tolerance induction without GVHD.